Prognostic value of low skeletal muscle mass in patient treated by exclusive curative radiochemotherapy for a NSCLC
Abstract Low skeletal muscle mass is a well-known prognostic factor for patients treated for a non-small-cell lung cancer by surgery or chemotherapy. However, its impact in patients treated by exclusive radiochemotherapy has never been explored. Our study tries to evaluate the prognostic value of lo...
Guardado en:
Autores principales: | R. Mallet, P. Decazes, R. Modzelewski, J. Lequesne, P. Vera, B. Dubray, S. Thureau |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/838097ce56c543438398c3f5fa881753 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
por: Mengqiu Tang, et al.
Publicado: (2021) -
Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients
por: Guido Kroemer, et al.
Publicado: (2021) -
Skeletal muscle mass at C3 may not be a strong predictor for skeletal muscle mass at L3 in sarcopenic patients with head and neck cancer.
por: Joon-Kee Yoon, et al.
Publicado: (2021) -
Prognostic and Predictive Effects of Positive Lymph Node Number or Ratio in NSCLC
por: Nan Ding, et al.
Publicado: (2017) -
Association between skeletal muscle mass and mammographic breast density
por: Kwan Ho Lee, et al.
Publicado: (2021)